Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside
PRAX Stock Soars on Historic Trial Win Praxis Precision Medicines stock has seen a record-breaking spike in recent days after announcing landmark clinical trial results. On October 16, PRAX shares closed at $162.71, up about 183% in a single session ts2.tech ts2.tech. The stock, which had closed at $57.35 the day prior, more than tripled to reach new 52-week highs ts2.tech. Intra-day, PRAX briefly touched as high as $205 as enthusiasm peaked google.com. By midday Thursday, the company was on track to add roughly $2.7 billion to its market capitalization if gains held ts2.tech – catapulting Praxis’s valuation from around $1 billion
